Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

The TRITON clinical trial programme: evaluation of the PARP inhibitor rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD)

Autor: E. Gez, Howard I. Scher, Gedske Daugaard, Brieuc Sautois, Josep M. Piulats, Simon Paul Watkins, Wassim Abida, Laurence Eliot Miles Krieger, Charles J. Ryan, Andrew Simmons, Florence Joly, Raymond S. McDermott, Alejo Rodriguez-Vida, Cora N. Sternberg, K. Fizazi, S. Shetty, T. Golsorkhi, J.A. Arranz Arija, Srikala S. Sridhar, Simon Chowdhury, Axel S. Merseburger, Axel Heidenreich, Jeremy Shapiro

Publikováno v: European Urology Supplements. 16:e2689-e2690

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3a39a3f95ca1ab9d1debd9ed8bdf0e69
https://doi.org/10.1016/s1569-9056(17)31836-5

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR -Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study.

Autor: Yang JC; Department of Oncology, National Taiwan University Hospital, Taipei City, Republic of China., Reckamp KL; Department of Medical Oncology, Cedars-Sinai Medical Center, Los Angeles, California., Kim YC; Department of Internal Medicine, Chonnam National University Hwasun Hospital, Hwasun-gun, Jeollanam-do, Republic of Korea., Novello S; Department of Oncology, University of Turin, Azienda Ospedaliero-Universitaria San Luigi Gonzaga, Orbassano, Italy., Smit EF; Department of Thoracic Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., Lee JS; Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea., Su WC; Department of Internal Medicine, National Cheng Kung University Hospital, Tainan City, Republic of China., Akerley WL; Medical Oncology, Huntsman Cancer Institute, Salt Lake City, Utah., Blakely CM; Division of Hematology/Oncology, Department of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California., Groen HJM; Department of Pulmonary Diseases, University of Groningen and University Medical Center Groningen, Groningen, The Netherlands., Bazhenova L; Division of Hematology and Medical Oncology, University of California San Diego Moores Cancer Center, La Jolla, California., Carcereny Costa E; Medical Oncology Department, Catalan Institute of Oncology Badalona, Badalona Applied Research Group in Oncology, Badalona, Spain., Chiari R; Medical Oncology, AULSS6 Euganea-Ospedali Riuniti Padova Sud, Padua, Italy., Hsia TC; Department of Respiratory Therapy, China Medical University, China Medical University Hospital, Taichung City, Republic of China., Golsorkhi T; Clinical Development, Clovis Oncology, Inc., Boulder, Colorado., Despain D; Biostatistics, Clovis Oncology, Inc., Boulder, Colorado., Shih D; Clinical Operations, Clovis Oncology, Inc., Boulder, Colorado., Popat S; Lung Unit, The Royal Marsden Hospital, Royal Marsden NHS Foundation Trust, London, United Kingdom., Wakelee H; Division of Oncology, Department of Medicine, Stanford University, Stanford, California.

Publikováno v: JTO clinical and research reports [JTO Clin Res Rep] 2020 Oct 26; Vol. 2 (2), pp. 100114. Date of Electronic Publication: 2020 Oct 26 (Print Publication: 2021).